JP7782951B2 - 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム - Google Patents

一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム

Info

Publication number
JP7782951B2
JP7782951B2 JP2020555291A JP2020555291A JP7782951B2 JP 7782951 B2 JP7782951 B2 JP 7782951B2 JP 2020555291 A JP2020555291 A JP 2020555291A JP 2020555291 A JP2020555291 A JP 2020555291A JP 7782951 B2 JP7782951 B2 JP 7782951B2
Authority
JP
Japan
Prior art keywords
lactis strain
lactis
lac4
strain
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508496A5 (cg-RX-API-DMAC7.html
JP2021508496A (ja
Inventor
キャスパー フフルリマン ハンス
ベフレンス マルティナ
ゲバウエル マンディ
ブレウニグ カリン
ベフレンス スヴェン‐エリク
Original Assignee
ベロワクチンズ ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベロワクチンズ ジーエムビーエイチ filed Critical ベロワクチンズ ジーエムビーエイチ
Publication of JP2021508496A publication Critical patent/JP2021508496A/ja
Publication of JP2021508496A5 publication Critical patent/JP2021508496A5/ja
Priority to JP2023132434A priority Critical patent/JP2023166412A/ja
Application granted granted Critical
Publication of JP7782951B2 publication Critical patent/JP7782951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
JP2020555291A 2017-12-27 2018-12-19 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム Active JP7782951B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023132434A JP2023166412A (ja) 2017-12-27 2023-08-16 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017012109.5A DE102017012109A1 (de) 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
DE102017012109.5 2017-12-27
PCT/DE2018/000379 WO2019129321A2 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023132434A Division JP2023166412A (ja) 2017-12-27 2023-08-16 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム

Publications (3)

Publication Number Publication Date
JP2021508496A JP2021508496A (ja) 2021-03-11
JP2021508496A5 JP2021508496A5 (cg-RX-API-DMAC7.html) 2022-01-06
JP7782951B2 true JP7782951B2 (ja) 2025-12-09

Family

ID=65817691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555291A Active JP7782951B2 (ja) 2017-12-27 2018-12-19 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム
JP2023132434A Pending JP2023166412A (ja) 2017-12-27 2023-08-16 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023132434A Pending JP2023166412A (ja) 2017-12-27 2023-08-16 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム

Country Status (18)

Country Link
US (2) US11905517B2 (cg-RX-API-DMAC7.html)
EP (1) EP3732293B1 (cg-RX-API-DMAC7.html)
JP (2) JP7782951B2 (cg-RX-API-DMAC7.html)
KR (1) KR102704217B1 (cg-RX-API-DMAC7.html)
CN (1) CN111801422B (cg-RX-API-DMAC7.html)
BR (1) BR112020013245A2 (cg-RX-API-DMAC7.html)
CA (1) CA3086598A1 (cg-RX-API-DMAC7.html)
DE (2) DE102017012109A1 (cg-RX-API-DMAC7.html)
DK (1) DK3732293T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091435A1 (cg-RX-API-DMAC7.html)
ES (1) ES2990197T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241297T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068358T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020006846A (cg-RX-API-DMAC7.html)
PL (1) PL3732293T3 (cg-RX-API-DMAC7.html)
PT (1) PT3732293T (cg-RX-API-DMAC7.html)
WO (1) WO2019129321A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202003553B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001417A1 (en) * 2020-11-13 2022-05-25 serYmun Yeast GmbH Yeast platform for the production of vaccines
WO2026119376A1 (de) 2024-12-03 2026-06-11 Verovaccines Gmbh Sedimentations-stabilisierte formulierungen für hefe-basierte vakzine
CN119391747B (zh) * 2024-12-12 2025-11-18 华中农业大学 一种利用马克斯克鲁维酵母制备禽传染性法氏囊病vp2纳米颗粒口服疫苗的方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528987A (ja) 2006-02-02 2009-08-13 グローブイミューン，インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
JP2010254721A (ja) 2002-12-16 2010-11-11 Globeimmune Inc 免疫療法としての酵母ベースのワクチン
JP2012524075A (ja) 2009-04-17 2012-10-11 グローブイミューン，インコーポレイテッド 癌に対する併用免疫療法組成物および方法
JP2015507472A (ja) 2011-12-13 2015-03-12 マーティン−ルター−ウニヴェアズィテート ハレ−ヴィッテンベアクＭａｒｔｉｎ−Ｌｕｔｈｅｒ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈａｌｌｅ−Ｗｉｔｔｅｎｂｅｒｇ 組み換え酵母を用いた、定義された抗原に対する防御的体液性免疫応答の生成による予防接種

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
KR20070068460A (ko) 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
DE102008057451A1 (de) 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010254721A (ja) 2002-12-16 2010-11-11 Globeimmune Inc 免疫療法としての酵母ベースのワクチン
JP2009528987A (ja) 2006-02-02 2009-08-13 グローブイミューン，インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
JP2012524075A (ja) 2009-04-17 2012-10-11 グローブイミューン，インコーポレイテッド 癌に対する併用免疫療法組成物および方法
JP2015507472A (ja) 2011-12-13 2015-03-12 マーティン−ルター−ウニヴェアズィテート ハレ−ヴィッテンベアクＭａｒｔｉｎ−Ｌｕｔｈｅｒ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈａｌｌｅ−Ｗｉｔｔｅｎｂｅｒｇ 組み換え酵母を用いた、定義された抗原に対する防御的体液性免疫応答の生成による予防接種

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biotechnol. Lett., (2004), Vol. 26, pp.1803-1808
J. Gen. Appl. Microbiol., (2017), Vol. 63, pp.199-202
PLOS ONE, (2015), Vol. 10, Issue 10, Article.e0139464

Also Published As

Publication number Publication date
EP3732293A2 (de) 2020-11-04
CN111801422A (zh) 2020-10-20
PT3732293T (pt) 2024-10-09
HUE068358T2 (hu) 2024-12-28
WO2019129321A3 (de) 2019-09-12
KR102704217B1 (ko) 2024-09-09
CN111801422B (zh) 2024-06-14
WO2019129321A2 (de) 2019-07-04
ZA202003553B (en) 2021-06-30
EP3732293B1 (de) 2024-07-03
HRP20241297T1 (hr) 2024-12-20
MX2020006846A (es) 2020-11-06
ES2990197T3 (es) 2024-11-29
DE102017012109A1 (de) 2019-06-27
PL3732293T3 (pl) 2024-11-18
DK3732293T3 (da) 2024-09-23
US20240102031A1 (en) 2024-03-28
KR20200104367A (ko) 2020-09-03
US12473562B2 (en) 2025-11-18
US20210230612A1 (en) 2021-07-29
EA202091435A1 (ru) 2020-08-28
US11905517B2 (en) 2024-02-20
BR112020013245A2 (pt) 2020-12-01
JP2021508496A (ja) 2021-03-11
CA3086598A1 (en) 2019-07-04
JP2023166412A (ja) 2023-11-21
DE112018006647A5 (de) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7113924B2 (ja) 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン
US9944952B2 (en) Replication-defective arenavirus vectors
US12473562B2 (en) Optimized host/vector system for producing protective mono-and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
Arnold et al. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit
JP6990814B2 (ja) アヒル腸炎ウイルス及びその使用
CN108368488B (zh) 鸭肠炎病毒及其用途
TW200924792A (en) A recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3) and a vaccine for the prevention of a disease caused by KHV/CyHV-3 in Cyorinus carpio carpio or Cyprinus carpio koi
JP6313215B2 (ja) 組み換え酵母を用いた、定義された抗原に対する防御的体液性免疫応答の生成による予防接種
ES2669018T3 (es) Procedimiento para la vacunación por vía oral/mucosa por medio de levaduras recombinantes
KR20260066090A (ko) 신규한 dev 벡터
CN121752290A (zh) Dev作载体的禽流感h9疫苗
CN101087886B (zh) 疱疹性口炎病毒、其载体和其免疫原性组合物的协同减毒
Loessner et al. Employing live microbes for vaccine delivery
EA045050B1 (ru) Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis
US20050019348A1 (en) Marek's disease virus vaccine
KR20260066088A (ko) 조류 백신을 위한 신규한 dev 벡터
HK1108114A (en) Aids vaccine based on replicative vaccinia virus vector

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230816

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230822

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250826

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251127

R150 Certificate of patent or registration of utility model

Ref document number: 7782951

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150